A Phase 3 interventional study of Tigulixostat and Placebo in Gout, Hyperuricemia and Gout Flare, sponsored by LG Chem. Completed at 52 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by LG Chem · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.
Among the 11 studies in Gout by LG Chem, this one is the 2nd largest by enrollment, is the only one that started in 2022, is one of 2 in phase 3, and was the 9th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 354 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 37 across the 11 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Gout by LG Chem, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tigulixostat 100mg, Once a day (QD) for up to 6 months
Drug: Tigulixostat
Tigulixostat 200mg, Once a day (QD) for up to 6 months
Drug: Tigulixostat
Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 6 months
Drug: Tigulixostat
Placebo, Once a day (QD) for up to 6 months
Drug: Placebo
Xanthine Oxidase Inhibitor
Also known as: LC350189
Matching placebo
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Time frame: Up to Month 6
The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Time frame: Up to Month 6
The proportion of subjects reporting a gout flare up to each visit.
Gout flare (intense pain, swelling, or/and tenderness in the joint area) will be assessed from baseline up to 6 months
Time frame: Up to Month 6
Incidence rate of adverse event
Safety assessment
Time frame: Up to Month 6
Plan to share: No
Ran from Oct 2022 to primary completion in Nov 2024, 24 months.
Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tigulixostat